Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.36 |
| ▸ | PRKCG | P05129 | 2/20 | 0.36 |
| ▸ | PRKCB | P05771 | 2/20 | 0.36 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | PRKCH | P24723 | 2/20 | 0.36 |
| ▸ | PRKCI | P41743 | 2/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611467 | 1.00 | ALDH1A1 (0.69) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL11615684 | 1.00 | ALDH1A1 (0.69) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL1463562 | 1.00 | ALDH1A1 (0.69) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL28284618 | 1.00 | ALDH1A1 (0.69) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL11694128 | 1.00 | ALDH1A1 (0.69) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL28042954 | 1.00 | ALDH1A1 (0.69) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL4618624 | 1.00 | ALDH1A1 (0.69) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL18092763 | 0.98 | ALDH1A1 (0.67) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL15301129 | 0.98 | ALDH1A1 (0.67) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 | |
| SCHEMBL2811229 | 0.98 | ALDH1A1 (0.67) | ALDH1A1EPHX1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167938-B | Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and medical uses thereof | 阿基利昂有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4029854-A1 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3470397-B1 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR | FIBROGEN INC (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-112028020-B | Process for recovering iodine from iodine bromide-containing medical organic waste liquid | 山东博苑医药化学股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-10981942-B2 | Crystalline form of benzylbenzene SGLT2 inhibitor | THERACOS SUB, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112028020-A | Process for recovering iodine from iodine bromide-containing medical organic waste liquid | 山东博苑医药化学股份有限公司 | 2020-12-04 | — | — | CN | disclosed |
| EP-3568396-B1 | NOVEL AMINO-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2020-11-11 | — | — | EP | disclosed |
| US-20200239510-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | THERACOSBIO, LLC | 2020-07-30 | — | — | US | disclosed |
| US-10703751-B2 | Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2020-07-07 | — | — | US | disclosed |
| US-20200115344-A1 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR | FIBROGEN INC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20090187040-A1 | FENOFIBRIC ACID POLYMORPHS; METHODS OF MAKING; AND METHODS OF USE THEREOF | MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION | 2009-07-23 | — | — | US | disclosed |
| WO-2009091967-A2 | FENOFIBRIC ACID POLYMORPHS; METHODS OF MAKING; AND METHODS OF USE THEREOF | MUTUAL PHARMACEUTICAL COMPANY (US) | 2009-07-23 | — | — | WO | disclosed |
| CN-101291921-A | Spiro [3.3] heptyl-dioxan derivatives and their use in liquid crystal media | MERCK PATENT GMBH (DE) | 2008-10-22 | — | — | CN | disclosed |
| EP-1878075-A2 | ELECTRODE MATERIAL INCLUDING A LITHIUM/TRANSITION METAL COMPLEX OXIDE | Phostech Lithium Inc. (CA) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006120332-A2 | ELECTRODE MATERIAL INCLUDING A LITHIUM/TRANSITION METAL COMPLEX OXIDE | PHOSTECH LITHIUM INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| US-5712270-A | TREATING PARKINSON*S DISEASE, DOWN*S SYNDROME, AND ALZHEIMER*S DISEASE WITH COGNITION ACTIVATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| US-5510478-A | TREATMENT OF NEUROLOGICAL ILLNESSES RELATED TO CHOLINERGIC DEFICIENCY; ALZHEIMERS'S DISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-23 | — | — | US | disclosed |
| US-4727151-A | CLEAVED TO DRUGS IN VIVO BY CHEMICAL OR ENZYMATIC HYDROLYSIS | INTERX RESEARCH CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| US-4178376-A | 6,8-DICHLORO-2-DIBUTYLAMINOMETHYL-2-(3',4'-DICHLOROPHENYL)-4 -QUINOLINEMETHANOL DISSOLVED IN SATURATED OR UNSATURATED FATTY ACID | INTERX RESEARCH CORPORATION (US) | 1979-12-11 | — | — | US | disclosed |
| US-4160099-A | Labile, non-heterocyclic quaternary ammonium salt/esters as transient derivatives | INTERX RESEARCH CORPORATION | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981942-B2 | Crystalline form of benzylbenzene SGLT2 inhibitor | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 2754/4885EPHX1 3768/4885CHRM2 4602/4885 |
| US-20200115344-A1 | CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR | P4HA1, ASPH, PAH | ALDH1A1 169/4885EPHX1 1002/4885CHRM2 4684/4885 |
| US-10703751-B2 | Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof | JAK1, JAK2, JAK3 | ALDH1A1 1419/4885EPHX1 3768/4885CHRM2 1181/4885 |
| US-20200239510-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | SLC5A2, SLC5A1, SLC2A4 | ALDH1A1 2754/4885EPHX1 3768/4885CHRM2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.